Core Viewpoint - Cumberland Pharmaceuticals Inc. will announce its 2025 financial results and provide a company update on March 3, 2026, after market close, followed by a conference call to discuss the results [1] Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for hospital acute care, gastroenterology, and oncology market segments [1] - The company’s portfolio includes several FDA-approved products such as Talicia®, Vibativ®, Vaprisol®, Sancuso®, Kristalose®, Caldolor®, and Acetadote® [1] Product Details - Talicia® is an oral capsule for treating H. pylori infection - Vibativ® is an injection for serious bacterial infections, including hospital-acquired pneumonia - Vaprisol® is an injection used to raise serum sodium levels in hospitalized patients - Sancuso® is a transdermal system for preventing nausea and vomiting in chemotherapy patients - Kristalose® is a prescription laxative for treating constipation - Caldolor® is an injection for pain and fever management - Acetadote® is an injection for treating acetaminophen poisoning [1] Clinical Programs - The company is conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [1]

Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company with a portfolio of FDA-approved branded products [6] - The company has three national sales divisions and several catalysts for new growth opportunities [6] - Cumberland has a proven record of successful product development and product acquisition [6] Product Portfolio - Acetadote is an IV treatment for acetaminophen overdose, developed and registered by Cumberland [11] - Caldolor is an injectable delivery of ibuprofen with antipyretic, analgesic & anti-inflammatory properties, approved for use in adults, children and newborns [15] - Kristalose is a unique crystalline formulation of lactulose, a prescription strength laxative [20] - Vibativ is an IV antibiotic that treats life-threatening infections resulting from gram-positive bacteria [24] - Sancuso is an FDA-approved transdermal system for chemotherapy-induced nausea and vomiting [29] - Ifetroban is Cumberland's first new chemical entity, a potent, selective antagonist of thromboxane receptor [30] Financial Performance (2024) - Net revenues were $37.9 million [51] - Gross profit was $31.3 million [51] - Adjusted earnings were $(1.0) million [51] - Cash and securities totaled $18.0 million as of December 31, 2024 [52] - The company has tax carryforward credits of $53 million available [52]